Document Detail


Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.
MedLine Citation:
PMID:  21969911     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare disease with a well-characterized pathogenesis. In 50% of the patients, LEMS is a paraneoplastic manifestation and caused by a small cell lung carcinoma (SCLC). Both LEMS patients with SCLC and those without this tumour have in 85% of cases pathogenetic antibodies of very high LEMS specificity against voltage-gated calcium channels (VGCCs) in the cell membrane of the presynaptic motor nerve terminal. Better understanding of LEMS pathogenesis has lead to targeted symptomatic therapy aimed at the neuromuscular junction and to semispecific immuno-suppression. For SCLC LEMS, tumour therapy is essential.
Authors:
Nils Erik Gilhus
Publication Detail:
Type:  Journal Article     Date:  2011-09-29
Journal Detail:
Title:  Autoimmune diseases     Volume:  2011     ISSN:  2090-0430     ISO Abbreviation:  Autoimmune Dis     Publication Date:  2011  
Date Detail:
Created Date:  2011-10-04     Completed Date:  2011-11-10     Revised Date:  2012-04-27    
Medline Journal Info:
Nlm Unique ID:  101546750     Medline TA:  Autoimmune Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  973808     Citation Subset:  -    
Affiliation:
Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-resolution optical coherence tomography retinal imaging: a case series illustrating potential a...
Next Document:  Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain ...